Mavatar

Exciting times! Mavatar Discovery, our first SaaS platform, is launching too. It is an innovative self-service solution tailor-made for pharmaceutical companies, CROs, researchers, and academia. Join our waiting list! Mavatar Discovery – Your key to computerized research & drug development ✅ Reduce time and cost ✅ Uncover new biological discoveries ✅ Streamline drug development Sing up here: https://lnkd.in/daZ7HP32 #AI, #DigitalTwins, #HealthcareInnovation,#PrecisionMedicine, #Mavatar #FutureOfMedicine Included is a minor sneak peek of the software.

How can AI and digital twins revolutionise healthcare and drug development? Mavatar is gearing up to take the stage at Medicon Village’s exclusive breakfast event on 25 March. Our CEO Johan Juhlin will be on stage and talk about how Mavatar's proprietary technology—backed by 20 years of research—fuels more informed treatment decisions and drives faster drug discovery. We are so looking forward to this! Stay tuned for insights from this exciting look into the future of precision medicine! #AI #DigitalTwins #HealthcareInnovation #PrecisionMedicine #Mavatar #FutureOfMedicine   https://lnkd.in/dgyBu8Bj

Right now, our CEO Johan Juhlin and CTO Fredrik Barrenäs are in the US, where they’ve had a series of really exciting meetings. They’re connecting with investors and potential clients – among them are some of the world’s largest pharmaceutical companies and internationally known figures such as: ➡️ Larry Silverstein – Businessman and real estate mogul who was involved in rebuilding the World Trade Center in New York. ➡️ Oscar Straus Schafer – Investment banker, philanthropist, former chairman of the New York Philharmonic, and current chairman of Rivulet Capital. ➡️ Andreas von Uexkull – Ambassador at the Government Offices, Ministry for Foreign Affairs. ➡️ Claudia Hidou, Business Sweden. This trip is a fantastic opportunity for us to forge new partnerships and open doors to future collaborations. #AI #DigitalTwins #HealthcareInnovation #PrecisionMedicine #Mavatar #FutureOfMedicine

Mavatar will be participating in FOKUS Patient ® Future Days on March 17–18, 2025. This year’s theme, “How do we tackle the main causes of ill health and death that are both communicable (CDs) and non-communicable diseases (NCDs)?” sets the stage for two days of vital discussions. Day 1 will focus on CDs—how changing attitudes toward democracy and trust in society affect healthcare, and crucial developments in AMR and vaccines. Day 2 will center on NCDs, including cancer and cardiovascular disease, as well as the growing challenge of comorbidity. We’re excited to contribute our data-driven AI approach to precision health, and to engage with healthcare professionals, policymakers, and industry leaders to explore new solutions that empower patients and improve outcomes. We look forward to meaningful conversations and collaborations at FOCUS Patient® Future Days.   Want to meet us there? Reach out to Max Garvell by clicking on the link below. https://lnkd.in/dTtfDRMK

Fantastiska nyheter! I Breakits senaste kartläggning av svenska AI-bolag uppmärksammades vi som en av de mest spännande aktörerna inom hälsa. Läs artiklen här: https://lnkd.in/dFrzpWbN Artikeln ligger bakom en betalvägg, men här är en kort sammanfattning om Mavatar: Mavatars datadrivna AI-plattform inom precisionshälsa har två affärsområden och används dels idag av biotechinriktade läkemedelsbolag och medicinska institutioner för att accelerera och effektivisera läkemedelsutveckling. Mavatar använder även samma grundplattform för att utveckla sitt egna blodprovsbaserade beslutsstöd till vården, idag inriktat främst mot onkologi, med syftet att alltid ge rätt medicinering i varje behandlingssteg och därigenom förbättra patienternas överlevnad och minimera ”trial & error”. Plattformen är baserad på över 20 års forskning kring hur substanser och individers biologi interagerar på molekylär nivå, med fokus på intra- och cell-till-cell-kommunikation samt transkriptomik. Plattformen använder sig av digitala tvillingar för att skapa avancerade sjukdomsmodeller. Mavatar grundades 2018 och leds av vd:n Johan Juhlin, som har erfarenhet från flera medtech-bolag. Bolaget har omkring 30 anställda, varav ca 25 är disputerade. Under 2024 tog Mavatar in 40 miljoner kronor till en värdering på 300 miljoner kronor, huvudsakligen från befintliga ägare som familjen Oldmark, Wictor Family Office, Maria Rankka och Johan Staël von Holstein. #AIinHealthcare, #AIinOncology, #CancerResearch,#PrecisionMedicine, #ClinicalTrials

Tack Patrik Rees for highlighting Mavatar 🙌 Indeed, we are a company to keep an eye on! As global specialists in precision healthcare solutions, we are the leading force in advancing AI-driven solutions that redefine how diseases are treated and cured. 🚀  

Imagine testing new treatments in a virtual world before they reach real patients. With Mavatar's AI-driven platforms, we’re making that a reality—transforming precision medicine and drug development like never before. By simulating diseases and human responses digitally, we can speed up research, refine treatments, and deliver personalized healthcare with unmatched accuracy. In Dagens Industri, our CEO, Johan Juhlin, shares how Mavatar is about to launch game-changing solutions in this space: https://lnkd.in/dc4tNvRm #AI #DigitalTwins #HealthcareInnovation #PrecisionMedicine #Mavatar #FutureOfMedicine

We’re hiring a Frontend Developer at Mavatar! The future of healthcare isn’t coming—it has arrived. AI is transforming patient care, accelerating drug development, and redefining what’s possible in medicine. At Mavatar, we’re leading this revolution, pioneering precision medicine to empower medical professionals to predict, personalize, and prevent like never before. Now, we’re looking for a Frontend Developer to help us with our mission! You’ll be part of a great team, working alongside our brilliant developers to build intuitive, powerful, and intelligent user interfaces that make cutting-edge technology accessible. 💬 Learn more and apply via the link in the comments. #hiring #frontend #react #AI #precisionmedicine #healthtech #development #mavatar

Pharma innovation isn’t just about new technology—it’s about shaping a culture of progress and impact. At Mavatar, we partner with forward-thinking pharmaceutical companies to accelerate drug development, from early target validation to full-scale clinical success—powered by AI. Medical leaders, clinical teams, and executives—consider Mavatar your trusted ally in delivering better treatments faster. We’re not just improving trials; we’re driving a new era of precision medicine. The question isn’t if these advancements will be adopted—it’s who will lead the way. Let’s shape the future of healthcare, together. #PharmaInnovation #AIinHealthcare #ClinicalExcellence #PrecisionMedicine #HealthcareTransformation

Innovation in pharma isn’t just about rolling out new tools—it’s about creating a culture that drives us forward. At Mavatar, we partner with progressive pharmaceutical companies ready to lead this transformation. From pre-target validation to full-scale drug development, our AI-driven approach helps accelerate and refine every step of the process. Medical directors, clinical teams, and executives—consider Mavatar your bold ally on the path to delivering better treatments, faster. Together, we’re not just shaping clinical trials; we’re forging a new era of medicine driven by intelligent innovation. The question isn’t if the industry will adopt these advances—it’s when. Let’s seize this moment and redefine healthcare together. Read more: www.mavatar.com Book a meeting:https://lnkd.in/dgVPA393 #PharmaInnovation,hashtag #ClinicalTrials,hashtag #TargetIdentification,hashtag #DrugRepurposing,hashtag #PrecisionMedicine,hashtag #PharmaceuticalResearch,hashtag #MechanismOfAction,hashtag #PharmaAI,hashtag #PrecisionDrugDevelopment,hashtag #DataDrivenDrugDiscovery